Candida auris in the neonatal intensive care unit

Area of Science:

• Medical Mycology
• Infectious Diseases
• Neonatal Care

Background:

• Candida auris is an emerging multidrug-resistant yeast causing healthcare-associated infections.
• Neonatal intensive care unit (NICU) infants are susceptible to Candida auris due to risk factors like antibiotic exposure and prematurity.
• Global outbreaks of Candida auris in NICUs have resulted in high mortality rates.

Purpose of the Study:

• To highlight the threat of Candida auris in NICUs.
• To discuss clinical presentation, treatment, and infection control measures for Candida auris in neonates.
• To identify knowledge gaps and areas for future research regarding Candida auris in this population.

Main Methods:

• Literature review and synthesis of existing data on Candida auris in NICUs.
• Analysis of clinical presentations, treatment strategies, and infection control protocols.
• Identification of research needs for optimal management and prevention.

Main Results:

• Candida auris infections in NICU infants present as late-onset sepsis, often indistinguishable from other causes.
• Echinocandins and amphotericin B are current empiric therapies.
• Infection prevention includes contact precautions, enhanced cleaning, and infant screening.

Conclusions:

• Candida auris is a critical pathogen in NICUs, demanding stringent infection control.
• Further research is needed on optimal antifungal therapy, screening sites, colonization duration, and transmission risks.
• Continued reporting of clinical experiences is essential for protecting neonates.